Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Cefuroxime sodium
Thea Pharmaceuticals Ltd
J01DC02
Cefuroxime sodium
50mg
Powder for solution for injection
Intracameral
No Controlled Drug Status
Valid as a prescribable product
BNF: 11080200; GTIN: 3662042002212
OBJECT 1 APROKAM CEFUROXIME 50MG POWDER FOR SOLUTION FOR INJECTION Summary of Product Characteristics Updated 18-Nov-2016 | Thea Pharmaceuticals Ltd 1. Name of the medicinal product APROKAM 50 mg powder for solution for injection 2. Qualitative and quantitative composition Each vial contains 50 mg of cefuroxime (as 52.6 mg of cefuroxime sodium). After reconstitution with 5 ml of solvent (see section 6.6), 0.1 ml solution contains 1 mg of cefuroxime. For the full list of excipients, see section 6.1. 3. Pharmaceutical form Powder for solution for injection [powder for injection]. White to almost white powder. 4. Clinical particulars 4.1 Therapeutic indications Antibiotic prophylaxis of postoperative endophthalmitis after cataract surgery (see section 5.1). Consideration should be given to official guidance on the appropriate use of antibacterial agents, including guidance on the antibiotic prophylaxis on eye surgery. 4.2 Posology and method of administration Intracameral use. One vial for single-use only. _POSOLOGY _ _Adults_: The recommended dose is 0.1ml of reconstituted solution (see section 6.6), i.e. 1mg of cefuroxime. DO NOT INJECT MORE THAN THE RECOMMENDED DOSE (see section 4.9). _Paediatric population_: The optimal dose and the safety of APROKAM have not been established in the paediatric population. _Elderly_: No dose adjustment is necessary. _Patients with hepatic and renal impairment_: Considering the low dose and the expected negligible systemic exposure to cefuroxime using APROKAM, no dose adjustment is necessary. _METHOD OF ADMINISTRATION _ APROKAM must be administered after reconstitution by intraocular injection in the anterior chamber of the eye (intracameral use), by an ophthalmic surgeon, in the recommended aseptic conditions of cataract surgery. After reconstitution, APROKAM should be inspected visually for particulate matter and discoloration prior to administration. Slowly inject 0.1ml of the reconstituted solution into the anterior chamber of the eye at the end of the cataract surgery. For in Read the complete document